Also known as Modified GRF (1-29) · Mod GRF 1-29
Modified GHRH(1-29) analog with short plasma half-life.
CJC-1295 without DAC is a 30-amino-acid analog of GHRH(1-29) with four substitutions that improve stability against DPP-4. Half-life ~30 minutes; commonly studied alongside GHRPs for pulsatile GH release.
CJC-1295 without DAC — also called Modified GRF(1-29) — is a 30-amino-acid analog of the first 29 residues of growth-hormone-releasing hormone (GHRH). Four amino-acid substitutions improve stability against the enzyme DPP-4 while preserving GHRH-receptor activity.
Without the Drug Affinity Complex (DAC), its plasma half-life is short — on the order of 30 minutes — so it produces a brief GH pulse. It is commonly studied alongside a GHRP such as ipamorelin, where the two receptor classes act synergistically. It is not FDA-approved.
GHRH receptor agonism on pituitary somatotrophs.
Behind every vial of CJC-1295 (no DAC) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how CJC-1295 (no DAC), specifically, is brought into being.
On paper, CJC-1295 (no DAC) is C165H269N47O46 — about 3,647.2 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling CJC-1295 (no DAC) means roughly 29 coupling cycles on the synthesizer — one protected residue added at a time, which is also 29 chances for an incomplete coupling to seed a deletion impurity.
The crude mixture — CJC-1295 (no DAC) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of CJC-1295 (no DAC) proves itself: identity confirmed by mass spectrometry against its ~3,647.2 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of CJC-1295 (no DAC) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing CJC-1295 (no DAC) to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning CJC-1295, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
It is a stabilized GHRH(1-29) analog (Modified GRF 1-29) studied for short, pulsatile growth-hormone release.
DAC (Drug Affinity Complex) is an albumin-binding addition that greatly extends half-life. Without it, the peptide acts briefly, producing a short GH pulse.
GHRH analogs and ghrelin-receptor agonists (GHRPs) act on different receptors; combining them is studied for synergistic GH release.
No — it is a research compound, not FDA-approved. This page is a research and educational reference.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.